Ampel BioSolutions is launching LuGENE, a blood test that uses artificial intelligence (AI) to look at a patient’s gene activity and predict when lupus flares are likely to happen and which medications could be most effective to keep symptoms in check. LuGENE is currently available through the company-sponsored…
News
FibroBiologics, a biopharmaceutical company that seeks to develop and commercialize fibroblast cell-based therapies, has filed an application with the United States Patent and Trademark Office covering the use of its technology to potentially treat lupus. Using its proprietary fibroblast platform, the Houston-based company aims to develop cures…
The U.S. Food and Drug Administration (FDA) has approved a clinical trial to evaluate the safety and effectiveness of Synthekine‘s two-component immunotherapy for the treatment of certain patients with lupus, without using lymphodepletion, a process in which chemotherapy is used beforehand to eliminate disease-causing immune cells. The multicenter, dose…
Three women with the autoimmune conditions systemic lupus erythematosus (SLE) and Sjögren’s syndrome saw their symptoms ease after starting a diet rich in plant-based raw foods, according to a recent case series report. The diet included mainly leafy greens, cruciferous vegetables, flax or chia seeds as a source of omega-3…
Lupus Therapeutics is collaborating with Artiva Biotherapeutics on a Phase 1 clinical trial testing AlloNK, a natural killer (NK) cell therapy candidate, in patients with lupus nephritis, which is one of the most common and severe complications of lupus that affects the kidneys. With a single clinical…
Seattle Children’s has been cleared by the U.S. Food and Drug Administration (FDA) to start the nation’s first clinical trial testing CAR T-cell therapy in children with systemic lupus erythematosus, the most common form of lupus. The trial, Reversing Autoimmunity through Cell Therapy (REACT-01), is targeted for a summer…
The Lupus Research Alliance (LRA) has announced the latest recipients of its Lupus Mechanisms and Targets Award (LMTA), who will investigate molecular pathways or targets that could lead to new or better treatments for lupus. Each of the seven awarded scientists will receive up to $600,000 in…
Immpact Bio has received an $8 million grant from the California Institute for Regenerative Medicine (CIRM) for its ongoing Phase 1b/2 study evaluating the safety and efficacy of IMPT-514 in people with active and treatment-resistant systemic lupus erythematosus (SLE), including those with active lupus nephritis. The open-label…
The U.S. Food and Drug Administration (FDA) has granted permission for Atara Biotherapeutics to test its lupus nephritis treatment candidate ATA3219 in a Phase 1 clinical trial involving lupus patients with this complication, which is marked by kidney damage and inflammation. The first patient is expected to be…
An arm of China’s National Medical Products Administration has given Kezar Life Sciences the green light to open sites in China for a Phase 2 clinical trial testing zetomipzomib in people with lupus nephritis, a severe complication of lupus characterized by kidney inflammation and damage. Kezar will run…
Recent Posts
- To my ‘forever nurse,’ who finally gave me my diagnosis of lupus
- New analyses show Benlysta may aid flare control, kidney health
- Can art therapy help lupus patients improve cognitive function?
- With chronic illness, checking in means asking, ‘How ya really doin’?’
- FDA approves Gazyva as lupus nephritis treatment